AAI/CML claims clinical material production time reductions of 65%

By .

- Last updated on GMT

Image: iStock/Supertruper
Image: iStock/Supertruper

Related tags: Pharmacology

AAIPharma and Cambridge Major Labs (CML) under a merged entity have driven efficiencies in end-to-end drug manufacturing, the firm says, dramatically reducing material delivery time.

AAI Pharma and CML merged in 2013​, to form a full-service contract manufacturing organisation (CMO) and two-and-a-half years on the firm has said the integration between the two units has led to “dramatic advancements in efficiency.”

According to the CMO, it has managed to manufacture and release late-stage clinical trial materials from an active pharmaceutical ingredient (API) made under GMP, through to the sterile drug product within 79 days.

This is around 65% of the 230 days AAI/CML said is the industry standard for non-integrated approaches, and marks the first time the company has produced both GMP API and GMP Drug Product in continuous end-to-end fashion.

“We have streamlined and integrated to create world class solution for small to mid-sized pharma & biotech companies for clinical trial material by providing a broad range of services across all seven of our sites and businesses,”​ CEO Stephan Kutzer said in a statement.

“Our technical and regulatory expertise differentiates AAI/CML as we proactively guide and advise our clients through all the clinical phases. The integrated manufacturing services further complement our ProForm SelectTM service offering for a fuller end-to-end solution.”

The announcement comes weeks after the CMO announced it was investing $11m (€10m)​ into a new facility at its Cortex innovation centre in St Louis, Missouri.

Related news

Show more

Related products

show more


Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

How will Brexit affect the Pharmaceutical Industry?

How will Brexit affect the Pharmaceutical Industry?

Source BioScience Ltd | 08-Mar-2018 | Technical / White Paper

Have you prepared your strategy for the outcome of Brexit to ensure that you can continue to supply the UK market?
Source BioScience is a CRO with...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers